Reata Pharma (RETA) Misses Q4 EPS by 76c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financials and Provides an Update on Development Programs
February 19, 2020 4:01 PM ESTPLANO, Texas, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata, the Company, or we), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on the Companys business and product development programs. Â
In 2019, we made significant progress toward our goal of becoming a global, fully-integrated biopharmaceutical company, said Warren Huff, Reatas Chief Executive Officer and President. We announced positive, pivotal data from our lead franchises, chronic kidney disease (CKD) and neurology, and are actively preparing for... More
